US$ 28.57
fda warning bpc 157 peptide 2024 2025 Most people hear “not approved” and immediately think unsafe or ineffective… but the reality is a lot more about economics than science. If something can't be patented, there's little incentive to FDA to weigh easing limits
Description
If the patient is critically ill, or has neurologic disease, an infectious disease or hyperthyroidism, considerably higher doses may be indicated

Mansour N, Paquette M, Ait-Mohand S, Dumulon-Perreault V, Gurin B
On the other hand, B12 has been shown to slow down the replication of the hepatitis C virus

Associated Press (AP)

Endocrinology, 146(7), 30523058
